KD026 / Sanofi - LARVOL DELTA

Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia (clinicaltrials.gov) - P2; N=5; Terminated; Sponsor: University of Texas Southwestern Medical Center; N=20 ➔ 5; Trial completion date: Dec 2020 ➔ Jun 2020; Active, not recruiting ➔ Terminated; Due to unavailability of the drug.

Enrollment change • Trial completion date • Trial termination • Dyslipidemia • Metabolic Disorders

Kadmon: BioCentury Future Leaders in the Biotech Industry Conference (Kadmon) - Anticipated expiry of composition of matter patent in US in 2026

Anticipated patent expiry • Dyslipidemia

Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia (clinicaltrials.gov) - P2; N=20; Active, not recruiting; Sponsor: University of Texas Southwestern Medical Center; Recruiting ➔ Active, not recruiting; Trial completion date: Jul 2019 ➔ Dec 2020; Trial primary completion date: Jul 2019 ➔ Jul 2020

Enrollment closed • Trial completion date • Trial primary completion date